

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1. – 48. (Canceled)

49. (Previously Presented) A method for preventing and/or treating a respiratory syncytial virus (RSV)-induced disease, the method comprising administering to a subject in need thereof a high affinity neutralizing immunoglobulin that specifically binds a RSV antigen with an affinity constant ( $K_a$ ) of at least  $10^{10} M^{-1}$  as measured by surface plasmon resonance.

50. (Previously Presented) A method for preventing and/or treating a RSV infection, the method comprising administering to a subject in need thereof a high affinity neutralizing immunoglobulin that specifically binds to a RSV antigen with a  $K_a$  of at least  $10^{10} M^{-1}$  as measured by surface plasmon resonance.

51. (Previously Presented) The method of claim 49, wherein the  $K_a$  is at least  $10^{11} M^{-1}$ .

52. (Previously Presented) The method of claim 50, wherein the  $K_a$  is at least  $10^{11} M^{-1}$ .

53. (Previously Presented) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin has an  $IC_{50}$  in a microneutralization assay that is less than the  $IC_{50}$  of the reference antibody IX-493.

54. (Previously Presented) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin has an  $IC_{50}$  of 2  $\mu g/ml$  to 10  $\mu g/ml$  in a microneutralization assay.

55. (Previously Presented) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin specifically binds to a RSV F antigen.

56. (Previously Presented) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin binds to the same epitope on RSV as the antibody composed of a heavy chain variable region (VH) having the amino acid sequence SEQ ID NO:2 (Figure 1B) and a light chain variable region (VL) having the amino acid sequence SEQ ID NO:1 (Figure 1A).

57. – 72. (Cancelled)

73. (Currently Amended) The method of claim 51 or 52, wherein the high affinity neutralizing immunoglobulin comprises:

- a. a VH CDR1 having the amino acid sequence TAGMSVG (SEQ ID NO:9);
- b. a VH CDR2 having the amino acid sequence DIWWDDKKDYNPSLKS (SEQ ID NO:7);
- c. a VH CDR3 having the amino acid sequence SMITNFYFDV (SEQ ID NO:11);
- d. a VL CDR1 having the amino acid sequence SASSSVGYMH (SEQ ID NO:3);
- e. a VL CDR2 having the amino acid sequence DTFKLAS (SEQ ID NO:12); and
- f. a VL CDR3 having the amino acid sequence FQGSFYPT (SEQ ID NO: 14) ~~or FQGSYYPT (SEQ ID NO:15).~~

74. (Previously Presented) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin is a tetrameric antibody, a Fab fragment, an F(ab)<sup>'</sup><sub>2</sub>, a heavy-light chain dimer, a single chain antibody, or a monoclonal antibody.

75. (Previously Presented) The method of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin is a humanized antibody.

76. – 78. (Cancelled)

79. (Previously Presented) The method of claim 73, wherein the high affinity neutralizing immunoglobulin is a tetrameric antibody, a Fab fragment, an F(ab)<sup>'</sup><sub>2</sub>, a heavy-light chain dimer, a single chain antibody, or a monoclonal antibody.

80. – 82. (Cancelled)

83. (Previously Presented) The method of claim of claim 49 or 50, wherein the high affinity neutralizing immunoglobulin comprises a light chain variable region having the amino acid sequence of SEQ ID NO:23 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:24.

84. (Cancelled)

85. (Previously Presented) The method of claim 49 or 50, wherein the subject is a human.